All In Biotech

Drug Trial Radar · NCT04503265

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies

Last checked: Nov 20, 2026Latest source record: May 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

122

Planned (sponsor's estimate)

Start

Aug 12, 2020

Primary completion

Aug 2026

Study completion Oct 2026

Sponsor

Lead sponsor
AtlasMedx, IncorporatedIndustry
Sponsor type
Industry
First posted
Aug 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.

Conditions

  • Advanced Malignant Neoplasm
  • Breast Cancer
  • Ovarian Cancer
  • Homologous Recombination Deficiency
  • Prostate Cancer
  • Pancreatic Cancer

Interventions

  • AMXI-5001:Dose Escalation Phase IDrug

    Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.

  • AMXI-5001:Dose Expansion Phase IIDrug

    Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the Maximum Tolerated Dose (MTD)Time frame: Approximately 12 months
  2. Determine the Recommended Phase 2 Dose (RP2D) for AMXI-5001 as monotherapyTime frame: Approximately 12 months
  3. Characterize safety profile of AMXI-5001Time frame: Approximately 24 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology

    Los Angeles, California · Recruiting

  • Johns Hopkins

    Baltimore, Maryland · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.